ライフサイエンスコーパス: growth inhibitor

1 e accelerated, consistent with its role as a growth inhibitor.

2 and by SMCs themselves, acts as a potent SMC growth inhibitor.

3 ison, ICI 182,780 is the more effective cell growth inhibitor.

4 poietic cells is abrogation of response to a growth inhibitor.

5 ereas palmitoleate (16:1Delta9) was a potent growth inhibitor.

6 tress-responsive tumor suppressor and potent growth inhibitor.

7 ave a role in synthesis of the lateral shoot growth inhibitor.

8 cule, an angiogenic factor, and a tumor cell growth inhibitor.

9 the absence of mitogen or in the presence of growth inhibitors.

10 sent a novel class of angiogenesis and tumor-growth inhibitors.

11 ction of multiple intracellular and secreted growth inhibitors.

12 -beta, antiestrogens, but not estrogens, are growth inhibitors.

13 m has yielded a number of potent cancer cell growth inhibitors.

14 MCs) by the expression of cell migration and growth inhibitors.

15 e growth arrest in response to extracellular growth inhibitors.

16 urally to OSM and LIF, were not active as EC growth inhibitors.

17 of anchorage-independent breast cancer cell growth inhibitors.

18 n primary cultured neurons exposed to axonal growth inhibitors.

19 cystine stones by rational design of crystal growth inhibitors.

20 e by molecules such as the myelin-associated growth inhibitors.

21 S), in particular regarding the role of axon-growth inhibitors.

22 0001 microg/mL) murine and human cancer cell growth inhibitors.

23 identified as a potential target of the cell growth inhibitor 5-fluorouracil.

24 RpL17 acts as a vascular smooth muscle cell growth inhibitor (akin to a tumor suppressor) and repres

25 y identified and characterized a novel tumor growth inhibitor and a fatty acid-binding protein in hum

26 ne (1) has been converted to the cancer cell growth inhibitor and antibiotic designated hystatin 2 (8

27 ing growth factor-beta (TGFbeta) is a potent growth inhibitor and inducer of apoptosis in B lymphocyt

28 4HPR concentrations at which it is a potent growth inhibitor and inducer of apoptosis.

29 ng growth factor beta (TGF-beta) is a potent growth inhibitor and inducer of cell death in B-lymphocy

30 t sequence homology to mouse mammary-derived growth inhibitor and thus was named mammary-derived grow

31 and will enable the design of more efficient growth inhibitors and facilitate an understanding of the

32 lyses attributed the regeneration failure to growth inhibitors and lack of intrinsic growth potential

33 Following SCI, axon growth inhibitors and other inflammatory responses preve

34 We propose a model in which a balance of growth inhibitors and promoters determines tissue growth

35 ence, despite the activation of a cascade of growth inhibitors and senescence markers, and are permis

36 ge-like cells secrete a variety of potent EC growth inhibitors and that one of these, OSM, is among t

37 Consequently, growth inhibitors and their common receptor have been id

38 ay be extended for the identification of new growth inhibitors and their targets across bacterial spe

39 sulfatide as a novel myelin-associated axon growth inhibitor, and provide evidence that sulfatide in

40 strate that mCLCA5 is a detachment-sensitive growth inhibitor, and suggest a mechanism whereby these

41 romote axon growth, remove myelin-associated growth inhibitors, and guide regenerating axons to their

42 We hypothesized that production of the growth inhibitor angiostatin increases during decreased

43 s of alpha-syn fibril growth and to identify growth inhibitors as a potential therapeutic approach in

44 e result of direct suppression of a few cell growth inhibitors at the early stage of miRNA overexpres

45 hydrolysate) and in the presence of several growth inhibitors (beta-glucoside, D-fucose, valine and

46 g growth factor beta-1 (TGFbeta-1) acts as a growth inhibitor, but in malignant cells it may act as a

47 in, often down-regulated in PCa, is a potent growth inhibitor by inducing G(0)/G(1) cell cycle arrest

48 Here, we show that a synthetic growth inhibitor called pyrabactin functions as a select

49 However, mutations in genes that encode growth inhibitors can trigger the onset of tumorigenesis

50 We found that the axon growth inhibitor chondroitin sulfate proteoglycan (CSPG)

51 We analyzed the effect of three putative growth inhibitors--chondroitin sulfate, serum albumin, a

52 nts led to synthesis of a potent cancer cell growth inhibitor designated phenstatin (3b).

53 led to the discovery of a potent cancer cell growth inhibitor designated phenstatin (5a).

54 The potency of these compounds as yeast growth inhibitors directly correlates with their lipophi

55 ded a practical synthesis of the cancer cell growth inhibitor dolastatin 18 (2, Dhex-(S)-Leu-(R)-N-Me

56 sentiality, and the identification of potent growth inhibitors either in vitro or in an infection mod

57 Here, we identified five growth inhibitors encoded by T7 bacteriophage.

58 sults reveal hCLCA2 as a novel p53-inducible growth inhibitor, explain how its down-regulation confer

59 growth factor beta1 (TGF-beta1) is a potent growth inhibitor for a variety of cultured cells.

60 log, was previously indicated to be a potent growth inhibitor for Hep 3B hepatoma cells in vitro.

61 ANUP is a strong growth inhibitor for KS cell lines, but has little or no

62 tions in the activation of TGFbeta, a potent growth inhibitor for most cell types, the degradation of

63 After CNS injuries, axon growth inhibitors from the myelin and the scar tissue at

64 A growth inhibitor, galectin-1, was downregulated in the h

65 Our data suggest that p202 is a growth inhibitor gene in prostate cancer cells and its e

66 Notably, we found a previously unidentified growth inhibitor, gene product (Gp) 0.6, that interacts

67 of (S)-(+)-tylophorine, a potent cancer cell growth inhibitor, has been accomplished in eight steps f

68 ctor beta1 (TGFbeta1), a potent keratinocyte growth inhibitor, has been shown to be overexpressed in

69 Compounds 3-6 were potent growth inhibitors (IC(50) 4.7-334 nM) of human tumor cel

70 Supporting its role as a primary growth inhibitor, IGFBP-3 production has been shown to b

71 rosis factor-mediated apoptosis, is a potent growth inhibitor in human prostate cancer (PCa).

72 findings couple the activity of an important growth inhibitor in liver to the induction of autophagy

73 etinol (AR), has long been known to act as a growth inhibitor in lymphocytes, whereas 14-hydroxy-4,14

74 hibitor of Src (as measured in vitro), and a growth inhibitor in NIH 3T3 cells.

75 Nogo-A is an important axonal growth inhibitor in the adult and developing CNS.

76 idance molecule A (RGMa) is a potent neurite growth inhibitor in the central nervous system, exerting

77 To prove that RpL17 acted as a growth inhibitor in vivo, we used pluronic gel delivery

78 U145, consistent with a role for beta1C as a growth inhibitor in vivo.

79 nique antineoplastic activity and are potent growth inhibitors in a variety of cultured cells.

80 available fluoro monosaccharides as putative growth inhibitors in Arabidopsis thaliana revealed that

81 ught to mediate the action of several axonal growth inhibitors in the adult brain and spinal cord.

82 se, but also to signals elicited by specific growth inhibitors in the context of a particular biologi

83 iral nucleoside treatment and not induced by growth inhibitors, in contrast to fungal dsRNA viruses.

84 DX2 negatively regulates the well-documented growth inhibitor insulin-like growth factor binding prot

85 On the {001} face, growth inhibitors like biuret compete with urea for the

86 er effects (NOEs), we define portions of the growth inhibitor likely to be accessible on the cell sur

87 f the crystal habit and polymorph by crystal growth inhibitors may not affect crystal aggregation or

88 Mammary derived growth inhibitor (MDGI) is a member of the family of cyt

89 1 and survivin and upregulation of the tumor growth inhibitor molecule p38 MAPK.

90 For growth inhibitors, mRNA expression for transforming grow

91 The target of such bacterial-growth inhibitors must be identified, and one way to ach

92 The myelin-derived neurite growth inhibitor Nogo has been proposed to play a major

93 binding two receptors for myelin-associated growth inhibitors, Nogo receptors 1 and 3.

94 that the biosynthetic pathway for this plant growth inhibitor occurs in root hair cells, involving a

95 ctor beta (TGF-beta) is known to be a potent growth inhibitor of breast cancer cells (BCCs), the sign

96 lls that survived chemotherapy but also as a growth inhibitor of cells that survived hypoxia.

97 However, trastuzumab is a better growth inhibitor of ECC-1TAM tumors where there is dimin

98 TGF-beta is a potent growth inhibitor of epithelial cells.

99 inst Cdc25B(2) in vitro and less potent as a growth inhibitor of human breast cancer cells.

100 more, we have found activin A to be a potent growth inhibitor of MCF- 7 cells (at 2 ng/ml), where it

101 hoxyethylamino-numonafide (MEAN) is a potent growth inhibitor of murine xenografts of 2 human HCC cel

102 This action of Slit2 as a growth inhibitor of retinal axons and the expression pat

103 The glycosaminoglycan heparin is a growth inhibitor of SMCs in vitro and in vivo.

104 1 and 3 except that 2 was a much more potent growth inhibitor of the two vulvar cell lines, which is

105 abino-hexopyranoside 2 was also an effective growth inhibitor of two drug-resistant leukemic cell lin

106 amino-1,4-naphthoquinone (PD-42), are potent growth inhibitors of 13 different human cancer cell line

107 (RA) have been demonstrated to be effective growth inhibitors of a number of human cancer cell lines

108 icular, semisynthetic analogue 5, are strong growth inhibitors of Mycobacterium tuberculosis H37Rv.

109 icrowave heating and evaluated as noteworthy growth inhibitors of Plasmodium falciparum (3D7 and W2)

110 A screen of fatty acids as growth inhibitors of Staphylococcus aureus revealed stru

111 evels of combined potency and selectivity as growth inhibitors of T. gondii and as inhibitors of the

112 pid A biosynthesis is required for bacterial growth, inhibitors of LpxC have potential utility as ant

113 In the adult mammalian CNS, the growth inhibitors oligodendrocyte-myelin glycoprotein (O

114 d has been used to quantitate the effects of growth inhibitors on cells in 96-well cultures.

115 ctions governing site-specific adsorption of growth inhibitors on crystal surfaces can be tailored in

116 GF-beta) serves as either an epithelial cell growth inhibitor or a tumor promoter, depending on the c

117 l myelinated CNS environment contains potent growth inhibitors or lacks growth-promoting molecules.

118 upling protein-2 (UCP-2) or (2) induction of growth inhibitor p21 leading to G1/S phase arrest was te

119 e whether the interactions between the human growth inhibitor p21WAF1 and PCNA from plants and humans

120 ion and stability of the ovarian cancer cell growth inhibitor peptide, LSCQLYQR (LR), is vital for le

121 y the target of a Mycobacterium tuberculosis growth inhibitor, pointed to a mechanism involving a sca

122 inase (MAPK) by endogenous growth factors or growth inhibitors provides a potential means of regulati

123 nophilin and small Ras family G protein cell growth inhibitor RASD1 genes.

124 A mammary-derived growth inhibitor-related gene (MRG) was previously ident

125 mmary gland and named it the mammary-derived growth inhibitor-related gene (MRG).

126 inhibitor and thus was named mammary-derived growth inhibitor-related gene (MRG).

127 Profiling of eight stereoisomeric T. cruzi growth inhibitors revealed vastly different in vitro pro

128 e of Rtn4b, the homologue of the rat neurite growth inhibitor RTN4-A/Nogo-A.

129 Here, we characterize a small, heat-stable growth inhibitor secreted by a rat T lymphoma line when

130 ulates RNA interference (RNAi) and acts as a growth inhibitor selectively in cancer but not in untran

131 central nervous system scar associated axon growth inhibitors, semaphorin 3A has been shown to be st

132 APF is therefore a frizzled-related peptide growth inhibitor shown to contain exclusively a transmem

133 non-permissive environment, including axonal growth inhibitors such as the Nogo-A protein.

134 It has been suggested that axon growth inhibitors, such as myelin-derived Nogo, prevent

135 enzymes, the LOX inhibitors were more potent growth inhibitors than the COX inhibitors.

136 results suggest that the prodrug is a potent growth inhibitor that can bypass dCK deficiency at highe

137 Thus, we have identified a novel growth inhibitor that is down-regulated by estrogens and

138 Pladienolide B (PB) is a potent cancer cell growth inhibitor that targets the SF3B1 subunit of the s

139 teoglycans (CSPGs) are a major class of axon growth inhibitors that are up-regulated after spinal cor

140 We also suggest that existence of growth inhibitors that counteract the action of Wingless

141 and synthetic modifiers tend to function as growth inhibitors that hinder solute attachment and impe

142 One hypothesis is that the nerve contains growth inhibitors that must be neutralized after injury

143 d that OKL38/OSGN1 (oxidative stress-induced growth inhibitor), the hub gene in the blue module, is a

144 erate is the presence of myelin-derived axon growth inhibitors, the role of which, however, remains p

145 The INK4a gene encodes two distinct growth inhibitors--the cyclin-dependent kinase inhibitor

146 operation and convert TGF-beta from a potent growth inhibitor to a tumor promoter are not fully under

147 We introduce the use of a growth inhibitor to enhance thin film conformality in lo

148 s a newly described membrane-bound astrocyte growth inhibitor to limit neuroplasticity, activity-depe

149 he mitogen IGF-II, promote activation of the growth inhibitor transforming growth factor beta, and re

150 survivin and Bcl-2 and downregulation of the growth inhibitor transforming growth factor-beta and pro

151 xpressed the oncogenes H-ras and raf and the growth inhibitor transforming growth factor-beta1.

152 nalyze the pathways that these two different growth inhibitors use for antagonizing breast cancer cel

153 Vascular endothelial cell growth inhibitor (VEGI), a member of the tumor necrosis

154 Vascular endothelial growth inhibitor (VEGI), a new member of the tumor necro

155 ell cDNA library, named vascular endothelial growth inhibitor (VEGI).

156 y, we report that human vascular endothelial growth inhibitor (VEGI, TNF superfamily 15), an endothel

157 Vascular endothelial growth inhibitor (VEGI; TNFSF15) has been shown to inhib

158 A novel human tumor growth inhibitor was identified by differential cDNA seq

159 Induction of most growth inhibitors was delayed but not abolished in cells

160 ion of growth cone responses to various axon growth inhibitors, we asked whether raising cAMP levels

161 The identities of the three EC growth inhibitors were confirmed by demonstrating that r

162 gram of cell cycle control in which numerous growth inhibitors were upregulated and mitogenic genes w

163 The most potent growth inhibitors where N-[methyl(4-phenylalkyl)]-3-amin

164 med RERG (ras-related and estrogen-regulated growth inhibitor), whose expression was decreased or los

165 The data show a novel class of growth inhibitors with a wide spectrum of action that in

166 ss of tubulin polymerization and cancer cell growth inhibitors with the potential to inhibit the Hedg

167 e of these, OSM, is among the most potent EC growth inhibitors yet reported.